Somite
Developer of an AI-native platform that predicts and controls cell fate by combining large-scale, sequential perturbation experiments in miniaturized culture with foundation-model machine learning. The company generates proprietary, context-rich single-cell datasets, trains transformer and continuous-time models to predict signal→state transitions, and applies those models to accelerate cell therapy process development, manufacturing comparability, and translational programs such as a Phase 2-ready allogeneic dopaminergic cell therapy for Parkinson’s disease.
Industries
Nr. of Employees
small (1-50)
Products
STEM-PD (investigational cell therapy)
A clinical-stage allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy for Parkinson’s disease intended to replace lost dopaminergic neurons; has completed first-in-human dosing and holds IND clearance for Phase 2 and FDA Fast Track designation.
STEM-PD (investigational cell therapy)
A clinical-stage allogeneic pluripotent stem cell-derived dopaminergic progenitor therapy for Parkinson’s disease intended to replace lost dopaminergic neurons; has completed first-in-human dosing and holds IND clearance for Phase 2 and FDA Fast Track designation.
Services
Use of foundation-model predictions and a reasoning layer to prioritize experiments and recommend protocol changes for differentiation and manufacturing comparability.
Generation of large-scale sequential signaling datasets using capsule split-and-pool experiments and single-cell readouts to train predictive models.
In silico simulation of context-specific drug effects, combination scheduling, and identification of small-molecule interventions for genetic or signaling defects.
Use of foundation-model predictions and a reasoning layer to prioritize experiments and recommend protocol changes for differentiation and manufacturing comparability.
Generation of large-scale sequential signaling datasets using capsule split-and-pool experiments and single-cell readouts to train predictive models.
In silico simulation of context-specific drug effects, combination scheduling, and identification of small-molecule interventions for genetic or signaling defects.
Expertise Areas
- Foundation-model development for biological systems
- High-throughput single-cell perturbation experiments
- Cell therapy process development and comparability
- Single-cell transcriptomics and data engineering
Key Technologies
- Split-and-pool capsule-based high-throughput culture
- Single-cell RNA sequencing
- Combinatorial perturbation screening
- Transformer-based neural networks
News & Updates
Agreement to acquire global rights to a Phase 2-ready allogeneic cell therapy program for Parkinson’s disease; Novo Nordisk also made a strategic investment.
Rebrand from Somite to Cellular Intelligence and publication of the technical white paper 'Engineering Cell Fate' describing the foundation-model approach and platform milestones.
Series A financing and public milestones on data scale and platform development that supported model training and expansion of therapeutic pipelines.
Strategic investment and collaboration with AMD Ventures to accelerate model training using high-performance GPU compute.
Appointment of a single-cell biology expert as Chief Scientific Officer to lead the integration of experimental biology, computational biology, machine learning, and translational science.
Addition of senior executives for strategy and marketing to support growth and commercialization planning.
Agreement to acquire global rights to a Phase 2-ready allogeneic cell therapy program for Parkinson’s disease; Novo Nordisk also made a strategic investment.
Rebrand from Somite to Cellular Intelligence and publication of the technical white paper 'Engineering Cell Fate' describing the foundation-model approach and platform milestones.
Series A financing and public milestones on data scale and platform development that supported model training and expansion of therapeutic pipelines.
Strategic investment and collaboration with AMD Ventures to accelerate model training using high-performance GPU compute.
Appointment of a single-cell biology expert as Chief Scientific Officer to lead the integration of experimental biology, computational biology, machine learning, and translational science.
Addition of senior executives for strategy and marketing to support growth and commercialization planning.